Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type : potential as a biomarker for diagnosis and CD27/CD70-targeted therapy
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
The engagement of CD27 on lymphocytes with its ligand, CD70, on tumors is believed to mediate tumor immune evasion and the elevation of serum soluble CD27 (sCD27) levels in patients with CD70-positive malignancies. We previously showed that CD70 is expressed in extranodal natural killer/T-cell lymphoma, nasal type (ENKL), an Epstein-Barr virus (EBV)-related malignancy. However, little is known about serum sCD27 expression and its association with the clinical characteristics of, and the CD27/CD70 interaction in, ENKL. In the present study, we show that serum sCD27 is significantly elevated in the sera of patients with ENKL. The levels of serum sCD27 provided excellent diagnostic accuracy for discriminating patients with ENKL from healthy subjects, correlated positively with the levels of other diagnostic markers (lactate dehydrogenase, soluble interleukin-2 receptor, and EBV-DNA), and decreased significantly following treatment. Elevated serum sCD27 levels also correlated significantly with advanced clinical stage and tended to correspond with shorter survival, in patients with ENKL. Immunohistochemistry indicated that CD27-positive tumor-infiltrating immune cells exist adjacent to CD70-positive lymphoma cells. In addition, serum sCD27 levels in patients with CD70-positive ENKL were significantly higher than those in patients with CD70-negative ENKL, suggesting that the intra-tumoral CD27/CD70 interaction boosts the release of sCD27 in serum. Furthermore, the EBV-encoded oncoprotein latent membrane protein 1 upregulated CD70 expression in ENKL cells. Our results suggest that sCD27 may serve as a novel diagnostic biomarker and also may serve as a tool for evaluating the applicability of CD27/CD70-targeted therapies by predicting intra-tumoral CD70 expression and CD27/CD70 interaction in ENKL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
Cancer immunology, immunotherapy : CII - 72(2023), 7 vom: 21. Juli, Seite 2087-2098 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nagato, Toshihiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 15.06.2023 Date Revised 26.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00262-023-03394-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353179493 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353179493 | ||
| 003 | DE-627 | ||
| 005 | 20240426233130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00262-023-03394-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM353179493 | ||
| 035 | |a (NLM)36811663 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nagato, Toshihiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type |b potential as a biomarker for diagnosis and CD27/CD70-targeted therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.06.2023 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a The engagement of CD27 on lymphocytes with its ligand, CD70, on tumors is believed to mediate tumor immune evasion and the elevation of serum soluble CD27 (sCD27) levels in patients with CD70-positive malignancies. We previously showed that CD70 is expressed in extranodal natural killer/T-cell lymphoma, nasal type (ENKL), an Epstein-Barr virus (EBV)-related malignancy. However, little is known about serum sCD27 expression and its association with the clinical characteristics of, and the CD27/CD70 interaction in, ENKL. In the present study, we show that serum sCD27 is significantly elevated in the sera of patients with ENKL. The levels of serum sCD27 provided excellent diagnostic accuracy for discriminating patients with ENKL from healthy subjects, correlated positively with the levels of other diagnostic markers (lactate dehydrogenase, soluble interleukin-2 receptor, and EBV-DNA), and decreased significantly following treatment. Elevated serum sCD27 levels also correlated significantly with advanced clinical stage and tended to correspond with shorter survival, in patients with ENKL. Immunohistochemistry indicated that CD27-positive tumor-infiltrating immune cells exist adjacent to CD70-positive lymphoma cells. In addition, serum sCD27 levels in patients with CD70-positive ENKL were significantly higher than those in patients with CD70-negative ENKL, suggesting that the intra-tumoral CD27/CD70 interaction boosts the release of sCD27 in serum. Furthermore, the EBV-encoded oncoprotein latent membrane protein 1 upregulated CD70 expression in ENKL cells. Our results suggest that sCD27 may serve as a novel diagnostic biomarker and also may serve as a tool for evaluating the applicability of CD27/CD70-targeted therapies by predicting intra-tumoral CD70 expression and CD27/CD70 interaction in ENKL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD27 | |
| 650 | 4 | |a CD70 | |
| 650 | 4 | |a Extranodal NK/T-cell lymphoma | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Soluble form | |
| 650 | 7 | |a CD27 Ligand |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Receptor Superfamily, Member 7 |2 NLM | |
| 650 | 7 | |a CD70 protein, human |2 NLM | |
| 700 | 1 | |a Komatsuda, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Ryusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Takahara, Miki |e verfasserin |4 aut | |
| 700 | 1 | |a Kishibe, Kan |e verfasserin |4 aut | |
| 700 | 1 | |a Yasuda, Shunsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yajima, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kosaka, Akemi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohkuri, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Oikawa, Kensuke |e verfasserin |4 aut | |
| 700 | 1 | |a Harabuchi, Shohei |e verfasserin |4 aut | |
| 700 | 1 | |a Kono, Michihisa |e verfasserin |4 aut | |
| 700 | 1 | |a Yamaki, Hidekiyo |e verfasserin |4 aut | |
| 700 | 1 | |a Wakisaka, Risa |e verfasserin |4 aut | |
| 700 | 1 | |a Hirata-Nozaki, Yui |e verfasserin |4 aut | |
| 700 | 1 | |a Ohara, Kenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Kumai, Takumi |e verfasserin |4 aut | |
| 700 | 1 | |a Katada, Akihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Harabuchi, Yasuaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Hiroya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer immunology, immunotherapy : CII |d 1982 |g 72(2023), 7 vom: 21. Juli, Seite 2087-2098 |w (DE-627)NLM012922226 |x 1432-0851 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2023 |g number:7 |g day:21 |g month:07 |g pages:2087-2098 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00262-023-03394-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2023 |e 7 |b 21 |c 07 |h 2087-2098 | ||